Pluri (PLUR) Granted U.S Patent for New Method
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- S&P 500, Nasdaq advance as oil eases ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- S&P Global explores potential separation of Capital IQ business
- Equities end higher as Anthropic's IPO filing buoys AI stocks
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
April 8, 2024 7:00 AM EDTPluris patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell therapy advancements and targets an estimated total addressable market of $11.66 billion by 2030
HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc. (Nasdaq: PLUR) (TASE:... More



